Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 18, Issue 3, 2017, Pages

  Nijst, Petra ^a,b   Verbrugge, Frederik H ^a   Martens, Pieter ^a,b   Bertrand, Philippe B ^a,b   Dupont, Matthias ^a   Francis, Gary S ^c   Tang, W H Wilson ^d   Mullens, Wilfried ^a,e  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c University of Minnesota Health Heart Care   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

Aldosterone; Biomarkers; Renin; Renin angiotensin system; Systolic heart failure

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NITRATE; RENIN; RENIN INHIBITOR;

ACUTE HEART FAILURE; ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CLINICAL FEATURE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG THERAPY; FEMALE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PLASMA RENIN ACTIVITY; PROGNOSIS; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VENOUS BLOOD; VOLUNTEER; AGED; BLOOD; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; KAPLAN MEIER METHOD; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; RENIN; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; TREATMENT OUTCOME;

EID: 85045882431     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320317729919     Document Type: Article

References (53)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–1435.
2. Cohn JN, Tognoni G and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.
3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
4. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
5. Brown MJ. Renin: Friend or foe? Heart 2007; 93: 1026–1033.
6. Castrop H, Höcherl K, Kurtz A, et al. Physiology of kidney renin. Physiol Rev 2010; 90: 607–673.
7. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–1729.
8. Vergaro G, Emdin M, Iervasi A, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol 2011; 108: 246–251.
9. Girerd N, Pang PS, Swedberg K, et al. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: Analysis from the EVEREST trial. Eur J Heart Fail 2013; 15: 1228–1235.
10. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007; 13: 9–20.
11. Skeggs LT Jr., Kahn JR, Lentz K, et al. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439–453.
12. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787–1847.
13. Verbrugge FH, Tang WH and Mullens W. Reninangiotensin- aldosterone system activation during decongestion in acute heart failure: Friend or foe? JACC Heart Fail 2015; 3: 108–111.
14. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239.
15. Verbrugge FH, Duchenne J, Bertrand PB, et al. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions. Am J Cardiol 2013; 112: 1913–1920.
16. Seikaly MG, Arant BS, Jr. and Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clinical Invest 1990; 86: 1352–1357.
17. van Kats JP, Danser AH, van Meegen JR, et al. Angiotensin production by the heart: A quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98: 73–81.
18. Vallotton MB, Gerber-Wicht C, Dolci W, et al. Interaction of vasopressin and angiotensin II in stimulation of prostacyclin synthesis in vascular smooth muscle cells. Am J Physiol 1989; 257 (5 Pt 1): E617–E624.
19. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274 (2 Pt 2): R263–R279.
20. Verbrugge FH, Dupont M, Steels P, et al. The kidney in congestive heart failure: ‘Are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’ Eur J Heart Fail 2014; 16: 133–142.
21. Shin SJ, Lim C, Oh SW, et al. The unique response of renin and aldosterone to dietary sodium intervention in sodium sensitivity. J Renin Angiotensin Aldosterone Syst 2014; 15: 117–123.
22. Lu H, Wu C, Howatt DA, et al. Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice. J Nutr Biochem 2013; 24: 49–53.
23. Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. Hypertension 2009; 54: 475–481.
24. Baker KM and Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259 (2 Pt 2): H610–H618.
25. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996; 93: 1148–1154.
26. Peng J, Gurantz D, Tran V, et al. Tumor necrosis factoralpha- induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. Circ Res 2002; 91: 1119–1126.
27. Weber KT. Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation 1997; 96: 4065–4082.
28. Brilla CG, Zhou G, Matsubara L, et al. Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809–820.
29. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137–139.
30. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103: 72–77.
31. Waeber B, Nussberger J, Perret L, et al. Experience with perindopril in normal volunteers. Arch Mal Coeur Vaiss 1989; 82 Spec No 1: 35–41.
32. Yasumura Y, Miyatake K, Okamoto H, et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J 2004; 68: 361–366.
33. Lees KR and Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol 1987; 23: 159–164.
34. Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002; 106: 1055–1057.
35. Sato A, Suzuki Y, Shibata H, et al. Plasma aldosterone concentrations are not related to the degree of angiotensinconverting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000; 23: 25–31.
36. Azizi M, Chatellier G, Guyene TT, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995; 92: 825–834.
37. Giles TD, Bakris G, Oparil S, et al. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. J Am Soc Hypertens 2015; 9: 845–854.
38. Hubers SA and Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 2016; 133: 1115–1124.
39. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129–2200.
40. Tiryaki O, Usalan C and Buyukhatipoglu H. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients. Nephrology (Carlton) 2010; 15: 211–215.
41. Sullivan JM, Ginsburg BA, Ratts TE, et al. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. Hypertension 1979; 1: 397–401.
42. Grossman E, Peleg E, Carroll J, et al. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994; 7: 1041–1044.
43. Tang WH, Vagelos RH, Yee YG, et al. Impact of angiotensin- converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am Heart J 2004; 148: 889–894.
44. Hannila-Handelberg T, Kontula KK, Paukku K, et al. Common genetic variations of the renin-angiotensinaldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. J Hypertens 2010; 28: 771–779.
45. Sato A and Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781–788.
46. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106: 367–372.
47. de Boer RA, Schroten NF, Bakker SJ, et al. Plasma renin and outcome in the community: Data from PREVEND. Eur Heart J 2012; 33: 2351–2359.
48. Dzau VJ and Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493–498.
49. Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium. Circulation 1997; 95: 1193–1200.
50. Santos RA. Angiotensin-(1–7). Hypertension 2014; 63: 1138–1147.
51. Patel VB, Lezutekong JN, Chen X, et al. Recombinant human ACE2 and the Angiotensin 1–7 axis as potential new therapies for heart failure. Can J Cardiol 2017; 33: 943–946.
52. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209–216.
53. Cugini P and Lucia P. Circadian rhythm of the renin-angiotensin- aldosterone system: A summary of our research studies [article in Italian]. Clinica Ter 2004; 155: 287–291.